Physician profile
Richard Rapp
NPI 1871521005
$47,022.84
in general payments reported to CMS, 2019-2025
32 companies · $94.28 in 2025
The $94.28 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $6,999 · 2021: $7,197 · 2022: $1,328 · 2023: $1,166 · 2024: $85.16 · 2025: $94.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345 · Education: $0.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.44 |
| Education | $0.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $18,692.03 | 2019-2023 | |
| Esperion Therapeutics, INC. | $9,203.32 | 2020-2021 | |
| Regeneron Pharmaceuticals, INC. | $9,042.58 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $3,804.29 | 2019 | |
| Lilly USA, LLC | $860.13 | 2019-2023 | Mounjaro, Jardiance, Humulin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $595.95 | 2020-2023 | Jardiance |
| Radius Health, INC. | $545.16 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $544.73 | 2019-2022 | |
| Medtronic Minimed, INC. | $397.37 | 2019 | |
| Abbvie INC. | $330.88 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $305.80 | 2022-2023 | |
| Amarin Pharma, INC. | $303.34 | 2019-2021 | |
| Abbott Laboratories | $288.04 | 2020-2025 | Freestyle Libre 3 |
| Kyowa Kirin, INC. | $229.79 | 2023-2024 | Crysvita |
| Dexcom, INC. | $212.33 | 2019-2023 | Dexcom G6 Transmitter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $200.23 | 2019-2023 | Repatha, Evenity, Prolia |
| Medtronic, INC. | $191.36 | 2021-2023 | Minimed 780g |
| Novo Nordisk INC | $190.29 | 2020-2023 | Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $177.95 | 2021-2023 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $167.76 | 2021-2022 | |
| Corcept Therapeutics | $127.76 | 2023 | Korlym |
| Janssen Pharmaceuticals, INC | $122.97 | 2019 | |
| Horizon Therapeutics Plc | $97.31 | 2022 | |
| Astellas Pharma US INC | $96.06 | 2023 | Veozah |
| Zealand Pharma US, INC. | $80.15 | 2020 | |
| Merck Sharp & Dohme LLC | $50.84 | 2020-2023 | Steglatro, Steglujan |
| Mannkind Corporation | $42.51 | 2023 | Afrezza |
| Amryt Pharma Holdings LTD | $31.15 | 2022 | |
| Ibsa Pharma INC. | $29.36 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $29.19 | 2022-2023 | |
| Recordati_rare_diseases_inc. | $20.40 | 2023 | Isturisa, Signifor Lar |
| Kowa Pharmaceuticals America, INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Rapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.